Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI

McMaster University

$25,000.00

Decrypting the Gut Microbiome to Identify New Therapies for NAFLD in Children and Adults

FY 2018-19

Summary
In Canada, over 30% of adults and 10% of children are affected with non-alcoholic fatty liver disease (NAFLD), a chronic condition often related to obesity. NAFLD refers to a range of conditions related to excess fat in the liver, unrelated to alcohol intake. NAFLD is a precursor to liver cirrhosis, end stage liver disease and is a major risk factor for liver cancer and is predicted to be the leading cause of cancer related death within the next 10 years. NAFLD is also an important risk factor for cardiovascular disease, type 2 diabetes and chronic kidney disease. Despite the prevalence and serious health implications of NAFLD, weight loss through lifestyle interventions (which has low long-term success) or bariatric surgery (which has increased risk of side effects) are currently the only methods to treat the disease. Therefore, designing new therapies including medications to treat NAFLD is critical. The development of NAFLD is complicated and involves several factors, such as the environment around us and many parts of the human body, including the liver, fat, muscle and the billions of bacteria that reside within our gastrointestinal tract or gut. In this proposal, we will conduct studies in mice and humans to examine how the bacteria in our gut and the substances (metabolites) they produce influence NAFLD. We will also examine if their influence is different in men and women and if their impact is different at different ages, from infants to adults. Thus, we are interested in how the metabolism of the bacteria in our gut regulates NAFLD and how the products of this metabolism could be targeted to create new interventions and therapies to treat NAFLD.
Program
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
399162
Name
Steinberg Gregory R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant : Canadian Microbiome Initiative 2: Research Teams
Projecttitle
Decrypting the Gut Microbiome to Identify New Therapies for NAFLD in Children and Adults
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI
Keyworddelim
Bacterial Culturing; Insulin Resistance; Nafld; Nash; Type 2 Diabetes
Abstract
In Canada, over 30% of adults and 10% of children are affected with non-alcoholic fatty liver disease (NAFLD), a chronic condition often related to obesity. NAFLD refers to a range of conditions related to excess fat in the liver, unrelated to alcohol intake. NAFLD is a precursor to liver cirrhosis, end stage liver disease and is a major risk factor for liver cancer and is predicted to be the leading cause of cancer related death within the next 10 years. NAFLD is also an important risk factor for cardiovascular disease, type 2 diabetes and chronic kidney disease. Despite the prevalence and serious health implications of NAFLD, weight loss through lifestyle interventions (which has low long-term success) or bariatric surgery (which has increased risk of side effects) are currently the only methods to treat the disease. Therefore, designing new therapies including medications to treat NAFLD is critical. The development of NAFLD is complicated and involves several factors, such as the environment around us and many parts of the human body, including the liver, fat, muscle and the billions of bacteria that reside within our gastrointestinal tract or gut. In this proposal, we will conduct studies in mice and humans to examine how the bacteria in our gut and the substances (metabolites) they produce influence NAFLD. We will also examine if their influence is different in men and women and if their impact is different at different ages, from infants to adults. Thus, we are interested in how the metabolism of the bacteria in our gut regulates NAFLD and how the products of this metabolism could be targeted to create new interventions and therapies to treat NAFLD.
Competitiondate
201811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Steinberg, Gregory R; MacNeil, Lesley T; Morrison, Katherine M; Schertzer, Jonathan D
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Infection & Immunity~ $25,000~ $0~